Insmed reported $76.44M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.


Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 232.28M 26.16M Jun/2025
Cytokinetics USD 65.72M 8.35M Jun/2025
DBV Technologies USD 6.81M 2.5M Jun/2025
Dynavax Technologies USD 41.54M 64.79M Jun/2025
Gilead Sciences USD 1.36B 100M Jun/2025
Insmed USD 76.44M 71.11M Jun/2025
Novartis USD 3.44B 60M Jun/2025
Regeneron Pharmaceuticals USD 634.2M 1.2M Jun/2025
Sarepta Therapeutics USD 69.89M 63.74M Jun/2025
Ultragenyx Pharmaceutical USD 86.65M 1.15M Jun/2025
Vertex Pharmaceuticals USD 424.6M 28.2M Jun/2025